ALZN - CIK 0001677077
The table below shows Alzamend Neuro, Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $3.95M | $376.05K | $5.14M | $14.06M | $1.93M |
| Short-term investments | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Total current assets | $4.18M | $455.24K | $5.84M | $14.41M | $2.91M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment |
| $425.61K |
| $176.35K |
| $79.84K |
| $102.91K |
| - |
| Goodwill | - | - | - | - | - |
| Total assets | $4.60M | $631.59K | $5.92M | $14.52M | $2.91M |
| Accounts payable | - | $2.93M | $2.87M | $1.16M | $503.59K |
| Total current liabilities | - | - | $2.87M | $1.16M | $899.64K |
| Long-term debt | - | - | - | - | - |
| Total liabilities | $634.76K | $3.23M | $2.87M | $1.16M | - |
| Retained earnings | -$58.54M | -$54.02M | -$44.07M | -$29.19M | -$16.83M |
| Total equity | $3.97M | -$2.59M | $3.05M | $13.35M | $2.01M |